-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Brand | Therapeutic category |
|---|---|
|
Aranesp |
Anti-anaemic preparation |
|
Eltroxin |
Hypothyroidism |
|
Mybulen |
Analgesic anti-inflammatory |
|
Solpadeine |
Opioid analgesic |
|
Stilpane |
Narcotic analgesic combinations |
|
Imuran |
Immunosuppressant |
| Brand | Therapeutic category |
|---|---|
|
Imuran |
Immunosuppressant |
|
Mara Moja |
Analgesic anti-inflammatory |
|
Mybulen |
Analgesic anti-inflammatory |
|
Stilpane |
Narcotic analgesic combinations |
|
Trustan |
Anti-ulcerant |
Launched
(2023: 40)
Recalls
(2023: 3)
Turnover
(2023: 11%)
Facilities
(2023: Nil)
Representatives
(2023: 212)
Employees
(June 2024)
Employees
(June 2023)
Launched
(2022: 25)
Recalls
(2022: 1)
Turnover
(2022: 13%)
Facilities
(2022: Nil)
Representatives
(2022: 218)
Employees
(June 2022: 3,945)
| Revenue |
2024 R’million |
2023 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
9 021 |
8 148 |
11 |
|
Prescription |
4 242 |
3 881 |
9 |
|
Over the counter |
3 561 |
3 496 |
2 |
|
Injectables |
1 218 |
771 |
58 |
|
Manufacturing |
486 |
683 |
(29) |
|
Active pharmaceutical ingredients |
270 |
199 |
36 |
|
Finished dose form |
216 |
484 |
(55) |
|
Total |
9 507 |
8 831 |
8 |
Note: Commercial Pharmaceuticals’ revenue is by customer geography and Manufacturing revenue is by place of manufacture.
| Revenue |
2023 R’million |
2022 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
8 154 |
8 523 |
(4) |
|
Regional Brands |
7 711 |
7 983 |
(3) |
|
Sterile Focus Brands |
443 |
540 |
18 |
|
Manufacturing |
646 |
2 051 |
>100 |
|
API Chemicals |
192 |
229 |
(16) |
|
FDF - Other |
11 |
22 |
(50) |
|
FDF - Steriles |
443 |
1 800 |
(75) |
|
Total |
8 800 |
10 574 |
(17) |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 79
- Africa Middle East 21
Revenue by segment (%)
- Prescription 45
- Over the counter 37
- Injectables 13
- Active pharmaceutical ingredients 3
- Finished dose form 2
- The South African private pharmaceutical sector was valued at R56,33 billion MAT* for the period ended July 2024, with a value growth of 1,10%.
- Aspen is the second-highest-ranked pharmaceutical company in the South African private sector, with an 8,79% share by value.
- Aspen, inclusive of the latest acquisitions of Eli Lilly Export S.A. (“Lilly”) and Applied Molecular Genetics Inc (“Amgen”), is now the leading pharmaceutical company in South Africa, with a combined value share of 10,23%.
Source: IQVIA July 2024.
* Moving annual total (“MAT”).
- The South African private pharmaceutical sector was valued at R54,5 billion MAT# for the period ended June 2023.
- Aspen has the second highest market share by value within the South African private sector, at 9,4%.
- By 2025, Middle East & Africa pharmaceutical market is collectively estimated to be USD56 billion, with United Arab Emirates and Egypt contributing 24,0% and 17,4% respectively.
- Middle East, North Africa & Turkey pharmaceutical market is expected to grow by 4,6% compound annual growth rate from 2021 to 2024, driven mainly by Turkey and Egypt.
Source: IQVIA June 2023. Sources: IQVIA TPM Moving Annual Total June 2022, IQVIA Middle East & Africa Pharmaceutical Market Insights. Released June 2022.
* Moving annual total (“MAT”).
